"Clever science with a commitment for life"
Hamol Biosolutions LLC is a privately-owned specialty biopharmaceutical company focused on the design, development, and manufacture of peptide-based biologic therapeutics. Over the years, the company has assembled a team of expert advisers in all aspects of pharmaceutical development, formulation, and regulatory affairs.
Headquartered in San Diego, USA, we were established in late 2009 to develop, and commercialize proprietary technology licensed on an exclusive basis from several academic institutions, both in the USA and Mexico.
"Developing smart therapeutic strategies to fight disease"
The Company develops products suitable for the pharmaceutical market satisfying an unmet medical need or exhibiting advantages over current therapies. Hamol Biosolutions’ line of products are manufactured under contract with Bioextracto S.A. de C.V., a biotechnology company located in the Mexican state of Queretaro, and with which Hamol Biosolutions has had a very fruitful working relationship over the years.
Taking into consideration that product development at Hamol Biosolutions encompasses several therapeutic areas, the Company has created a strong commitment to the fields of cardiovascular medicine and infection-related research. Hamol Biosolutions close ties with academic institutions, both in the United States of America and Mexico enables access to promising projects at an early stage. After licensing these projects, the Company performs feasibility and development studies through pre-clinical and clinical investigation. Supported by a distinguished panel of scientific advisers and regulatory experts, the Company advances the pipeline through Phase II proof of concept in humans. At this stage, the Company usually seeks a medium-size or large pharmaceutical company to complete clinical development and bring the product to market.
"Delivery value for patients through innovation"
Hamol Biosolutions proprietary technologies and product development obtained through collaboration with academic institutions, give us the edge in developing innovative possibilities with therapeutically advantageous properties. The ability to combine our understanding of unmet patient needs in the fields of cardiovascular medicine and infection-related research with our cutting-edge technology has resulted in original new therapeutic possibilities.
Our competitive advantages include:
|Description||R&D||Preclinical||Phase 1||Phase 2|
|Description||R&D||Clinical laboratory||Market availability|
Hamol Biosolutions designs, optimizes, and develops peptide-based therapeutics in the fields of atherosclerosis and infection-related conditions such as septic shock. Hamol Biosolutions currently has two early-stage preclinical development programs: HB-ATV-8 a needle-free mucosal therapeutic vaccine to prevent and treat atherosclerosis entering Phase 1 development, and HB-SCT-16 a peptide to treat severe complications caused by lipopolysaccharides during Gram-negative bacterial infections. Hamol Biosolutions through its diagnostics program has developed HB-CETP, a diagnostic kit designed to measure the levels of the Cholesterol-Ester Transfer Protein (CETP) in human plasma. This kit is close to validation and soon reaching the market.
HB-ATV-8: Patent granted Mexico, WO2014003531; Patent granted United States of America, US 9,539,312 B2; Patent granted European Community, EP2868327.
HB-SCT-16: International patent application, PCT/MX2014/00087.
HB-CETP: Patent granted Mexico, 246945; Patent granted European Community, 1242446; Patent granted United States of America, US7749721 B2; Patent application Canada, 2,525,539.
Luna-Reyes I, Pérez-Hernández E, Ávila-Rodríguez M.A. and Mas-Oliva J.
The VSAK peptide derived from the carboxy-terminal región of CETPI as a therapeutic agent in sepsis and septic shock: A FDG-PET study.
Scientific Reports (submitted)
Pérez-Hernández E, De la Puente V, Luna-Reyes I, Delgado-Coello B, Sifuentes-Osornio J, and Mas-Oliva J.
Peptide VSAK and CETPI as new biomarkers in sepsis and septic shock.
Nature Medicine (submitted)
Molecular events involved in the efficacy of therapeutic vaccine HB-ATV-8.
Atherosclerosis, 315, e138 (2020)
Toledo-Ibelles P and Mas-Oliva J.
Antioxidants in the fight against atherosclerosis: is this a dead end?.
Current Atherosclerosis Reports 20:36 (2018). doi.org/10.1007/s11883-018-0737-7
Gutiérrez-Vidal R, Calixto-Tlacomulco S, Méndez-Acevedo K, Delgado-Coello B,Damián-Zamacona S and Mas-Oliva J.
Therapeutic intranasal HB-ATV-8 vaccine prevents atherogenesis and non-Alcoholic fatty liver disease in a pig model of atherosclerosis.
Archives of Medical Research 49; 436-470 (2018).
Luna-Reyes I, Pérez-Hernández E, Ávila-Rodríguez M.A. and Mas-Oliva J.
The process of septic shock is attenuated by the intravenous administration of Peptide VSAK: A FDG-PET study.
Intensive Care Medicine Experimental 6; 1-33 (2018)
García-González V and Mas-Oliva J.
β-adaptin/c-Myc Interactions Modulated by Oxidative Stress in the Control of the Cell Cycle.
Scientific Reports 7; (2017). doi:10.1038/s41598-017-13880-5
Tapia-Vieyra V and Mas-Oliva J.
Atherosclerosis and cancer; A resemblance with far-reaching implications.
Archives of Medical Research 48:115-124 (2017)
Mas-Oliva J, Delgado-Coello B, Méndez-Acevedo K, Gutiérrez-Vidal R, Calixto-Tlacomulco S.
Preclinical evidence studying intranasal HB- ATV-8 vaccine in a porcine model of atherosclerosis shows high efficiency in the prevention of atherogenesis and fatty liver disease.
Atherosclerosis 263:52 (2017) (doi.org/10.1016/j.atherosclerosis.2017.06.177)
García-González V, Pérez-Torres A, Delgado-Coello B, and Mas-Oliva J.
The reality of a vaccine in the prevention and treatment of atherosclerosis.
Archives of Medical Research 46: 427-437 (2015)
Mas-Oliva J., and García-González V.
CETPI defines its function as a novel plasma LPS-binding protein with implications in the treatment of septic shock.
Critical Care 20:357 (2016) (doi: 10.1186/s13054-016-1518-8)
Mas-Oliva J, Delgado-Coello B, Méndez-Acevedo K.
Novel intranasal anti-CETP vaccine against the development of atherosclerosis and fatty liver disease.
Atherosclerosis 252:238 (2016) (doi.org/10.1016/j.atherosc 2016.07.020)
Damián-Zamacona S, Toledo-Ibelles, P, S. Ibarra-Abundis, M.Z. Toledo-Ibelles, P. Uribe-Figueroa, L. Hernández-Lemus, E. Macedo-Alcibia, K.P. Delgado-Coello, B. Mas-Oliva, J. and Reyes-Grajeda, J.P.
Early transcriptomic response to LDL and oxidized-LDL in human vascular smooth muscle cells.
PlosOne 11(10):e0163924. doi:10.1371/journal.pone.0163924 (2016)
García-González, V. Guitiérrez-Quintanar, N. and Mas-Oliva, J.
The C-terminus domain of CETPI defines its function as a new plasma lipopolysaccharide-binding protein.
Scientific Reports 5; 2015 doi:10.1038/srep16091
Mendoza-Espinosa, P. Montalvan-Sorrosa, D. García-González, V. Moreno, A. Castillo R. and Mas-Oliva J.
Microenvironmentally controlled secondary structure motifs of apolipoprotein AI (apoA-I) derived peptides.
Molecular and Cellular Biochemistry. 393, 99-109 (2014)
García-González V, Gutiérrez-Quintanar N, Mendoza-Espinosa P, Brocos P, Piñeiro and Mas-Oliva J.
Key structural arrangements at the C-terminus domain of CETP suggest a potential mechanism for lipid-transfer activity.
Journal of Structural Biology 186, 19–(2014) doi.org/10.1016/j.jsb.2014.02.002
García-González V, Mas-Oliva J.
Amyloid fibril formation of peptides derived from the C-terminus of CETP modulated by lipids.
Biochemical and Biophysical Research Communications 434: 54-59 (2013)
García-González V and Mas-Oliva J
Amyloidogenic Properties of a D/N Mutated 12 Amino Acid Fragment of the C-Terminal Domain of the Cholesteryl-Ester Transfer Protein (CETP)
International Journal of Molecular Sciences. 12, 2019-2035, (2011).
"We appreciate your visit to our site and thank you for your interest in our company"